A5090894020- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Pancreatitis Pathology and Treatment
- Pharmaceutical Economics and Policy
- Atrial Fibrillation Management and Outcomes
- Ethics and Legal Issues in Pediatric Healthcare
- Health Systems, Economic Evaluations, Quality of Life
- Venous Thromboembolism Diagnosis and Management
- Blood Pressure and Hypertension Studies
- Family and Disability Support Research
- Pharmaceutical Practices and Patient Outcomes
- Cystic Fibrosis Research Advances
Australian National University
2018-2021
Deloitte (United States)
2020
Royal Children's Hospital
2017
Abstract Background and aims Non-alcoholic steatohepatitis (NASH) – a progressive subset of non-alcoholic fatty liver disease (NAFLD) is chronic that can progress to advanced fibrosis, cirrhosis, end-stage (ESLD) if left untreated. Early-stage NASH usually asymptomatic, meaning large proportion the prevalent population are undiagnosed. Receiving diagnosis increases probability patient will receive interventions for purpose managing their condition. The this study was estimate burden economic...
Objectives To quantify changes in anticoagulant use Australia since the introduction of Non-vitamin K antagonist anticoagulants (NOACs) and to estimate government expenditure. Design Interrupted-time-series analysis quantifying dispensing, before after first Pharmaceutical Benefits Scheme (PBS) NOAC listing August 2009 for venous thromboembolism prevention; expanded stroke prevention non-valvular atrial fibrillation (AF) 2013, up June 2016. Estimated expenditure on PBS-listed anticoagulants....
Background NASH is a chronic disease which can progress to end-stage liver (ESLD) if left untreated. There high risk of particularly rapid progression ESLD in people with advanced fibrosis due NASH, few whom are diagnosed and under treater care the EU5 countries. This study aims estimate prevalence socioeconomic burden associated its treatment countries during 2018.